Residual Cancer Burden in Locally Advanced Breast Cancer
Author Information
Author(s): Zeina Nahleh, Sivasubramaniam D., Dhaliwal S., Sundarajan V., Komrokji R.
Primary Institution: Wayne State University, Karmanos Cancer Institute
Hypothesis
The study aims to explore the association between tumor characteristics, treatment response, and outcomes in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
Conclusion
The residual cancer burden (rcb) score is a better predictor of outcomes following neoadjuvant chemotherapy in locally advanced breast cancer than the pathologic complete response (pcr).
Supporting Evidence
- 22% of patients achieved pathologic complete response (pcr).
- None of the patients with inflammatory breast cancer achieved pcr.
- Higher rcb scores were associated with lower event-free survival (efs) and overall survival (os).
- Patients with estrogen receptor-negative tumors were more likely to achieve pcr than those with positive tumors.
- rcb was found to be a continuous predictor of distant relapse-free survival.
Takeaway
This study looked at how much cancer is left after treatment in women with advanced breast cancer, finding a new way to measure it that might help doctors predict how well patients will do.
Methodology
The study involved a retrospective chart review of patients diagnosed with locally advanced breast cancer who received neoadjuvant chemotherapy, with analysis of pathology slides to calculate the residual cancer burden.
Limitations
The study had a small sample size and limited events, which may affect the reliability of the conclusions.
Participant Demographics
The median age of participants was 51 years, with 40% white and 60% black patients.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 1.47 to 2.55
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website